Ignite Creation Date:
2024-05-05 @ 10:17 AM
Last Modification Date:
2024-10-26 @ 9:05 AM
Study NCT ID:
NCT00005931
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
2000-06-30
Brief Title:
SU5416 in Patients With AIDS-Related Kaposis Sarcoma Who Have Not Responded to Treatment
Sponsor:
SUGEN
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
A Multicenter Open-Label Phase II Study of SU5416 in Patients With Therapy-Refractory Cutaneous AIDS-Related Kaposis Sarcoma
Status:
COMPLETED
Status Verified Date:
2000-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to test the effectiveness of SU5416 in patients with AIDS-related Kaposis sarcoma KS
Detailed Description:
Patients are given SU5416 via twice-weekly intravenous infusions in 4-week treatment cycles Any patient who has not experienced unacceptable toxicity and who is deemed to be responding to the study drug no evidence of disease progression is permitted to continue receiving SU5416 in 4-week treatment cycles up to a maximum of 1 year of therapy until that patient experiences either unacceptable toxicity or tumor progression as defined in the protocol
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| SU5416027 | None | None | None |